Cambria Pharmaceuticals is a privately held biopharmaceutical company focused on discovering innovative treatments for serious neurological disorders, leveraging genetic research and academic collaborations.
Import Shipments
Distribution Centers
Annual Revenue
Founded
Cambria Pharmaceuticals is likely advancing its lead neurological drug candidates, expanding research collaborations, and seeking additional funding in line with industry trends toward precision medicine and rare disease therapeutics.
Progression of ALS drug candidate through preclinical or early clinical stages
Strategic efforts to expand market presence and reach new customer segments.
Implementation of advanced technologies to improve service delivery and customer experience.
Cambria Pharmaceuticals is dedicated to the discovery and development of novel therapeutics targeting serious neurological disorders, including ALS. The company employs advanced genetic research to engineer disease models and identify promising compounds. Collaborative relationships with academic institutions and foundations are central to its approach, enabling progress in both lead and exploratory programs. Cambria’s strategic focus is on creating disease-modifying treatments for high-profile neurological diseases with significant unmet needs.
Woburn, Massachusetts
2008
Private company
